Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 19 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 27 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2021 Results presented in the TG Therapeutics Media Release.